Lab
Permanente Medical Group, INC.
Permanente Medical Group, INC. was paid $31.35M by Medicaid between Jan 2018 and Dec 2024, across 142 billing codes. Its largest line is 87591, Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe — 8.1% of everything it billed.
33Billing provider infoPERMANENTE MEDICAL GROUP, INC.
BERKELEY, CA 94710
BERKELEY, CA 94710
33aNPI1083777163assigned 12/19/2006
33bProvider typeClinical Medical Laboratory
28Total paid$31.35M
24GClaims3,171,096
24DCodes billed142
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#32 of 561
Median peer was paid$222K
This provider vs. median141×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 328,677 | $237K | |
| 2019 | 351,687 | $362K | |
| 2020 | 308,190 | $1.95M | |
| 2021 | 454,340 | $3.27M | |
| 2022 | 462,081 | $3.69M | |
| 2023 | 482,064 | $3.95M | |
| 2024incomplete | 784,057 | $17.91M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 8.1% | 249,248 | 214,381 | $2.55M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 8.1% | 248,960 | 214,402 | $2.54M |
| 87506 | 6.6% | 18,583 | 18,428 | $2.07M | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 5.7% | 171,688 | 164,084 | $1.78M |
| 82274 | 5.2% | 157,839 | 156,512 | $1.62M | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 5.0% | 147,369 | 146,964 | $1.56M |
| 86235 | 4.7% | 16,137 | 15,994 | $1.49M | |
| 88185 | 3.7% | 1,813 | 1,725 | $1.16M | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 3.7% | 148,792 | 147,085 | $1.15M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 3.6% | 43,391 | 42,686 | $1.12M |
| 88341 | 2.8% | 6,077 | 5,953 | $882K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2.5% | 95,421 | 93,715 | $792K |
130 more codes
| 86803 | 2.4% | 143,565 | $759K | |
| 82043 | 2.4% | 149,213 | $758K | |
| 87088 | 2.4% | 173,698 | $751K | |
| 86780 | 2.2% | 157,840 | $693K | |
| 88342 | 1.8% | 12,236 | $572K | |
| 84165 | 1.8% | 20,475 | $570K | |
| 87517 | 1.7% | 16,535 | $522K | |
| 86003 | 1.6% | 19,494 | $511K | |
| 87536 | 1.6% | 10,213 | $496K | |
| 87340 | 1.3% | 112,368 | $420K | |
| 82570 | 1.3% | 85,625 | $401K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 143,195 | $312K |
| 83516 | <1% | 35,241 | $296K | |
| 88142 | <1% | 76,681 | $276K | |
| 88312 | <1% | 4,175 | $245K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 2,352 | $236K |
| 88344 | <1% | 1,305 | $225K | |
| 86706 | <1% | 49,078 | $224K | |
| 86140 | <1% | 89,862 | $212K | |
| 86704 | <1% | 31,752 | $199K | |
| 82784 | <1% | 17,025 | $165K | |
| 88313 | <1% | 2,108 | $162K | |
| 88184 | <1% | 1,840 | $156K | |
| 88360 | <1% | 624 | $152K | |
| 83020 | <1% | 12,964 | $143K | |
| 86225 | <1% | 19,095 | $137K | |
| 88112 | <1% | 4,144 | $135K | |
| 87209 | <1% | 18,526 | $132K | |
| 84156 | <1% | 58,747 | $130K | |
| 87070 | <1% | 29,036 | $121K | |
| 87631 | <1% | 11,314 | $119K | |
| 86334 | <1% | 2,381 | $118K | |
| 88189 | <1% | 1,338 | $117K | |
| 87529 | <1% | 9,899 | $114K | |
| 86038 | <1% | 17,644 | $106K | |
| 86762 | <1% | 30,203 | $102K | |
| 86160 | <1% | 12,369 | $100K | |
| 87329 | <1% | 18,030 | $92K | |
| 87522 | Neg quan hep c or qual rna | <1% | 3,772 | $91K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 4,046 | $73K |
| 88173 | <1% | 1,003 | $69K | |
| 84134 | <1% | 5,083 | $67K | |
| 86665 | <1% | 8,697 | $67K | |
| 86200 | <1% | 11,413 | $66K | |
| 87102 | <1% | 24,953 | $63K | |
| 88307 | <1% | 748 | $62K | |
| 86708 | <1% | 10,779 | $55K | |
| 86255 | <1% | 3,207 | $55K | |
| 83498 | <1% | 7,001 | $52K | |
| 87521 | Neg quan hep c or qual rna | <1% | 1,815 | $48K |
| 88365 | <1% | 226 | $47K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 6,976 | $47K |
| 86480 | <1% | 971 | $46K | |
| 88304 | <1% | 4,483 | $42K | |
| 86431 | <1% | 15,579 | $42K | |
| 84466 | <1% | 5,667 | $42K | |
| 86787 | <1% | 13,854 | $38K | |
| 87081 | <1% | 26,345 | $37K | |
| 87040 | <1% | 6,410 | $35K | |
| 86664 | <1% | 8,691 | $30K | |
| 87116 | <1% | 3,254 | $30K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 3,060 | $26K |
| 83010 | <1% | 2,528 | $26K | |
| 82390 | <1% | 4,919 | $25K | |
| 82103 | <1% | 3,556 | $24K | |
| 86765 | <1% | 10,641 | $24K | |
| 86709 | <1% | 4,365 | $23K | |
| 86735 | <1% | 9,925 | $23K | |
| 86696 | <1% | 3,704 | $22K | |
| 87538 | <1% | 1,316 | $19K | |
| 82384 | <1% | 864 | $19K | |
| 86593 | <1% | 10,017 | $19K | |
| 87535 | <1% | 1,250 | $19K | |
| 82164 | <1% | 1,988 | $16K | |
| 87075 | <1% | 1,496 | $15K | |
| 86769 | <1% | 1,881 | $14K | |
| 86695 | <1% | 3,239 | $14K | |
| 87206 | <1% | 3,218 | $13K | |
| 83835 | <1% | 1,032 | $13K | |
| 85097 | <1% | 165 | $13K | |
| 88364 | <1% | 62 | $13K | |
| 82239 | <1% | 2,439 | $13K | |
| 83695 | <1% | 2,605 | $9K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,322 | $8K |
| 86008 | <1% | 399 | $6K | |
| 86335 | <1% | 44 | $5K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 569 | $5K |
| 82955 | <1% | 1,017 | $5K | |
| 82530 | <1% | 344 | $5K | |
| 84166 | <1% | 56 | $4K | |
| 88104 | <1% | 37 | $4K | |
| 87328 | <1% | 598 | $3K | |
| 83883 | <1% | 92 | $3K | |
| 99284 | Emergency room visit (serious) | <1% | 116 | $3K |
| 86060 | <1% | 1,080 | $3K | |
| 82340 | <1% | 191 | $2K | |
| 86162 | <1% | 121 | $1K | |
| 99283 | Emergency room visit (moderate) | <1% | 67 | $1K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 20 | $756.31 |
| 86677 | <1% | 2,270 | $611.10 | |
| 88108 | <1% | 26 | $352.62 | |
| 86618 | <1% | 577 | $306.98 | |
| 87045 | <1% | 81 | $304.88 | |
| 86705 | <1% | 19 | $280.00 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 841 | $265.20 |
| 87177 | <1% | 31 | $217.95 | |
| 87327 | <1% | 13 | $200.00 | |
| 87172 | <1% | 54 | $154.18 | |
| 87350 | <1% | 422 | $145.56 | |
| 82310 | <1% | 13 | $95.06 | |
| 86707 | <1% | 263 | $44.36 | |
| 87799 | <1% | 223 | $39.11 | |
| 86320 | <1% | 272 | $23.93 | |
| 88141 | <1% | 47 | $10.53 | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | 0% | 598 | $0.00 |
| 87902 | 0% | 43 | $0.00 | |
| G0143 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with manual screening and rescreening by cytotechnologist under physician supervision | 0% | 480 | $0.00 |
| 3078F | 0% | 61 | $0.00 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 0% | 12 | $0.00 |
| 90658 | 0% | 63 | $0.00 | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | 0% | 1,483 | $0.00 |
| 90674 | 0% | 20 | $0.00 | |
| 86580 | 0% | 16 | $0.00 | |
| 99214 | Doctor's office visit, returning patient (more involved) | 0% | 12 | $0.00 |
| 90656 | 0% | 12 | $0.00 | |
| 99285 | Emergency room visit (most serious) | 0% | 26 | $0.00 |
| 3074F | 0% | 63 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 147 | $0.00 |
| 90686 | 0% | 64 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWEST, PATRICIA (CHIEF FINANCIAL OFFICER)
Parent organizationPERMANENTE MEDICAL GROUP, INC.
| Provider | Location | Paid |
|---|---|---|
| Permanente Medical Group INC | Stockton, CA | $125.88M |
| Permanente Medical Group, INC. | Richmond, CA | $51.11M |
| Permanente Medical Group INC | Richmond, CA | $37.82M |
| Permanente Medical Group INC | Vallejo, CA | $16.13M |
| Permanente Medical Group INC | Santa Clara, CA | $8.46M |
| Permanente Medical Group INC | San Francisco, CA | $5.40M |
| Permanente Medical Group INC | Redwood City, CA | $4.45M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.